These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31375514)

  • 1. Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study.
    Lamarca A; Ronot M; Moalla S; Crona J; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Bezerra ROF; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Scaefer N; Baudin E; Sundin A; Costa F; Pavel M; Dromain C
    Clin Cancer Res; 2019 Nov; 25(22):6692-6699. PubMed ID: 31375514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability.
    Dromain C; Sundin A; Najran P; Vidal Trueba H; Dioguardi Burgio M; Crona J; Opalinska M; Carvalho L; Franca R; Borg P; Vietti Violi N; Schaefer N; Lopez C; Pezzutti D; de Mestier L; Lamarca A; Costa F; Pavel M; Ronot M
    Neuroendocrinology; 2021; 111(9):831-839. PubMed ID: 32717738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
    Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
    BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ; Whitman J; Paciorek A; Le BK; Nakakura EK; Behr SC; Joseph N; Zhang L; Hope TA; Bergsland EK
    J Neuroendocrinol; 2023 Apr; 35(4):e13260. PubMed ID: 37002881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.
    He LN; Zhang X; Li H; Chen T; Chen C; Zhou Y; Lin Z; Du W; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Front Oncol; 2020; 10():621329. PubMed ID: 33552993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.
    Ramtohul T; Cohen A; Rodrigues M; Piperno-Neumann S; Cabel L; Cassoux N; Lumbroso-Le Rouic L; Malaise D; Gardrat S; Pierron G; Mariani P; Servois V
    Br J Cancer; 2022 Jul; 127(2):258-267. PubMed ID: 35347325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
    Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
    Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of tumor growth rate in evaluating the early therapeutic efficacy of neuroendocrine neoplasm].
    Zhou YT; Xia YF; Li Y; Zhu YJ; Chi Y; Jiang L
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1000-1006. PubMed ID: 35399019
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.
    Pettersson OJ; Fröss-Baron K; Crona J; Sundin A
    Endocr Connect; 2021 Apr; 10(4):422-431. PubMed ID: 33875614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
    de Mestier L; Lamarca A; Hernando J; Zandee W; Alonso-Gordoa T; Perrier M; Walenkamp AM; Chakrabarty B; Landolfi S; Van Velthuysen MF; Kats-Ugurlu G; Caminoa A; Ronot M; Manoharan P; Garcia-Alvarez A; Brabander T; García Gómez-Muriel MI; Cadiot G; Couvelard A; Capdevila J; Pavel ME; Cros J
    Endocr Relat Cancer; 2021 Jun; 28(8):549-561. PubMed ID: 34061764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
    Caruso D; Polici M; Rinzivillo M; Zerunian M; Nacci I; Marasco M; Magi L; Tarallo M; Gargiulo S; Iannicelli E; Annibale B; Laghi A; Panzuto F
    Radiol Med; 2022 Jul; 127(7):691-701. PubMed ID: 35717429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
    Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
    J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.
    Li BT; Drilon A; Johnson ML; Hsu M; Sima CS; McGinn C; Sugita H; Kris MG; Azzoli CG
    Ann Oncol; 2016 Jan; 27(1):154-9. PubMed ID: 26487589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRRT genomic signature in blood for prediction of
    Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
    Winkelmann M; Blumenberg V; Rejeski K; Quell C; Bücklein V; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.